How has been the historical performance of Cryogenic OGS?

Cryogenic OGS has shown steady growth in net sales and profitability over the past three years, with net sales increasing from 22.02 Cr in Mar'23 to 32.90 Cr in Mar'25, and profit after tax rising from 4.08 Cr to 6.09 Cr. The company maintains a healthy balance sheet with no long-term borrowings and improved cash flow.

Answer:<BR>The historical performance of Cryogenic OGS shows a steady growth in net sales and profitability over the past three years.<BR><BR>Breakdown:<BR>Cryogenic OGS has demonstrated a consistent increase in net sales, rising from 22.02 Cr in Mar'23 to 24.25 Cr in Mar'24, and further to 32.90 Cr in Mar'25. Total operating income mirrored this trend, reaching 32.90 Cr in Mar'25. However, raw material costs also increased significantly, from 11.70 Cr in Mar'23 to 21.26 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 16.37 Cr in Mar'23 to 24.94 Cr in Mar'25, yet the operating profit (PBDIT) improved from 6.34 Cr in Mar'23 to 8.85 Cr in Mar'25. Profit before tax also saw an upward trajectory, increasing from 5.48 Cr in Mar'23 to 8.27 Cr in Mar'25, while profit after tax rose from 4.08 Cr to 6.09 Cr in the same period. The earnings per share (EPS) increased from 3.89 in Mar'23 to 5.8 in Mar'25. On the balance sheet, total assets grew from 23.95 Cr in Mar'23 to 33.73 Cr in Mar'25, with total liabilities also increasing from 23.95 Cr to 33.73 Cr. The company maintained no long-term borrowings, and cash and cash equivalents rose from 8.10 Cr in Mar'23 to 11.07 Cr in Mar'25, indicating a positive cash flow position. Overall, Cryogenic OGS has shown robust growth in sales and profitability, alongside a healthy balance sheet.

Is Cryogenic OGS overvalued or undervalued?

As of October 17, 2025, Cryogenic OGS is considered very expensive and overvalued with a PE ratio of 42.91, despite recent strong stock returns of 17.08% and 22.98% over the past week and month, respectively, making it an unfavorable investment at its current price of 183.00.

As of 17 October 2025, the valuation grade for Cryogenic OGS has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued based on its key financial ratios, including a PE ratio of 42.91, an EV to EBITDA ratio of 29.49, and a Price to Book Value of 5.23. <BR><BR>When compared to its peers, Cryogenic OGS stands out with a higher PE ratio than Thermax at 55.98 and BEML Ltd at 61.47, both of which are also classified as very expensive. The company has shown strong returns over the past week and month, outperforming the Sensex with a stock return of 17.08% and 22.98%, respectively. However, despite these short-term gains, the overall valuation suggests that Cryogenic OGS is not a favorable investment at its current price of 183.00.

Which are the latest news on Cryogenic OGS?

Why is Cryogenic OGS falling/rising?

As of 03-Dec, Cryogenic OGS Ltd's stock price is at 185.00, down 1.6% and showing short-term weakness as it trades below several moving averages. Investor participation has decreased, with a notable drop in delivery volume, contributing to the stock's decline.

As of 03-Dec, Cryogenic OGS Ltd's stock price is falling, currently at 185.00, which reflects a decrease of 3.0 points or 1.6%. The stock has underperformed compared to the sector by 0.63% today and has experienced a trend reversal after two consecutive days of gains. Additionally, the stock reached an intraday low of Rs 180, marking a decline of 4.26%. <BR><BR>In terms of trading activity, there has been a notable decrease in investor participation, with delivery volume dropping by 6.11% compared to the 5-day average. Although the stock is trading above its 100-day and 200-day moving averages, it is below the 5-day, 20-day, and 50-day moving averages, indicating a short-term weakness. Overall, these factors contribute to the current decline in Cryogenic OGS Ltd's stock price.